Immunopharmacologic therapy in renal transplantation

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 562-575

  Shoker, Ahmed S ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 2 (3 DIMETHYLAMINOPROPYL) 8,8 DIPROPYL 2 AZASPIRO[4.5]DECANE; AZATHIOPRINE; BREQUINAR; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; IMMUNOTOXIN; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEW DRUG; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS;

ALLOGRAFT; DRUG TOLERANCE; GENE INDUCTION; GENE TRANSFER; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; REVIEW; SURVIVAL RATE;

FORECASTING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0029820263     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Takemoto S, Terasaki PI, Gjertson DW, Cecka JM. Equitable allocation of HLA-compatible kidneys for local pools and for minorities. N Engl J Med 1994;331(12):760-4.
2. Gjertson D. Survival trends in long-term first cadaver-donor kidney transplants. In: Terasaki PI, Cecka JM, eds. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1991:225-35.
3. Didlake RH, Dreyfus K, Kerman RH, et al. Patients' noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. In: Kahan BD, ed. Cyclosporine; therapeutic use in transplantation. Orlando, FL: Grune & Stratton, 1988:63-9.
4. Terasaki PR, Cecka JM, Lim E, et al. Overview. In: Terasaki P, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1990:409-30.
5. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen. Transplantation 1994;57(9):1295-1302.
6. Bach FH, Sachs DH. Current concepts: immunology. N Engl J Med 1987;317:489-92.
7. Weiss A, Littman DF. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-74.
8. Fresa K, Hameed M, Cohen S. Intracellular mechanisms of lymphoid cell activation. Clin Immunol Immunopathol 1989;50:8-19.
9. Clippstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-7.
10. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature 1991;352:803-7.
11. Suthanthiran M, Strom TB. Renal transplantation. N Engl J Med 1994;331(6):365-76.
12. Duijvestijn AM, van Breda Vriesman PJC. Chronic renal allograft rejection. Transplantation 1991;52:195-202.
13. Isoniemi H, Nurminen M, Tikkanen MJ, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994;57(1):68-72.
14. Möller G, ed. Chronic graft rejection. Immunol Rev 1993;134.
15. Paul LC, Benediktsson H. Post-transplant hypertension and chronic renal allograft failure. Kidney Int 1995;48(suppl 52):S34-7.
16. Shoker AS, Genesis R, George DH, Baltzan RB, Baltzan MA. Can acute cellular rejection occur 27 years after successful renal transplant? Transplantation 1994;58(10):1131-43.
17. Dorf ME, Benacerraf B. Suppressor cells and immunoregulation. Annu Rev Immunol 1984;2:127-57.
18. Reinsmoen NL, Matas AJ. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation 1993;55:1017-23.
19. Kelly M, Gebel H, Jensik S, et al. Rejection of renal allografts: prediction with a new peripheral blood assay. Curr Surg 1989;46(1):13-15.
20. Goulmy E, Blokland E, Persijn G, Paul LC, Wilmink J, Van Rood J. HLA regulates postrenal transplant CML nonreactivity. J Immunol 1985;135:3028-86.
21. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752-7.
22. Dupont E. Molecular and cellular mechanisms of action of drugs used to modulate the immune response. Semin Thorac Cardiovasc Surg 1990;2:175-80.
23. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA. FK-506 and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992;357:692-4.
24. Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J 1994;8:391-400.
25. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251: 283-7.
26. Mickey R, Cho YW, Carnahan E. Long-term graft survival in clinical transplants 1990. In: Terasaki PI, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1991;385-96.
27. Thiel G, Bock A, Spondlin M, et al. Long-term benefits and risks of cyclosporine A (Sandimmune) - an analysis at 10 years. Transplant Proc 1994;26(5):2493-8.
28. Winkler M, Brinkmann C, Jost U, Oldhafer K, Ringe B, Pichlmayr R. Long-term side effects of cyclosporine-based immunosuppression in patients after liver transplantation. Transplant Proc 1994;26(5):2679-82.
29. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994;57(7):979-89.
30. Schwartz R, Dameshek W. The effects of 6-mercaptopurine on homograft reactions. J Clin Invest 1960;39:952-8.
31. White DJ. FK506: the promise and the paradox. Clin Exp Immunol 1991;83:1.
32. Thomson AW, Carroll PB, McCauley J, et al. FK506: a novel immunosuppressant for treatment of autoimmune disease. Semin Immunopathol 1993;14:323-44.
33. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992;69:1227-36.
34. Sigal NH, Dumont FJ. Cyclosporine A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992;10:519-60.
35. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992;6:39-87.
36. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358:70-3.
37. Thomson AW, Woo J, Fung JJ, Starzl TE. FK506: pharmacology and molecular action. In: Bach JF, ed. T-cell directed immunointervention. Oxford: Blackwell, 1993:138-53.
38. Suzuki N, Sakane T, Tsunematsu T. Effects of a novel immunosuppressive agent, FK506, on human B-cell activation. Clin Exp Immunol 1990;79:240-5.
39. Klaus G. Cyclosporine-sensitive and cyclosporine-insensitive modes of B cell stimulation. Transplantation 1988;46:11S-14.
40. Starzl TE, Fung J, Venkataramanan R, Todo S, Demetris AJ, Jain A. FK506 for liver, kidney and pancreas transplantation. Lancet 1989;2(8670):1000-4.
41. Ferraresso M, Kahan BD. Immunopharmacology of rapamycin. J Immunol Immunopharmacol 1993;12:252-5.
42. Almond PS, Moss A, Nakhleh RE, et al. Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation 1993;56:275-81.
43. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506 and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991;23:521-4.
44. Makowka L, Sher LS, Cramer DV. The development of brequinar as an immunosuppressive drug for transplantation. Immunol Rev 1993;136:51-70.
45. Elion GB. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898-904.
46. Chen SF, Ruber R, Dexter D. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluor-1,1′-biphenyl-4-yl)-3-methyl-4- quinolinecarboxylic acid sodium salt (NSC 368390). Inhibition of de novo pyrimide nucleotide biosynthesis. Cancer Res 1986;46:5014-19.
47. Arteaga CL, Brown TD, Kuhn JG, et al. Phase I clinical and pharmacokinetic trial of brequinar sodium (DUP 785; NSC 368390). Cancer Res 1989;49:4648-53.
48. Turka LA, Dayton J, Sinclair G, Thompson CB, Mitchell BS. Guanine ribonucleotide depletion inhibits T cell activation: mechanism of action of the immunosuppressive drug mizoribien. J Clin Invest 1991;87:940-8.
49. Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992;41:671-6.
50. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
51. Sweeney MJ, Hoffman DH, Esterman MA. Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972;32:1803-9.
52. Figueroa J, Fuad SA, Kunjummen BD, Platt JL, Bach FH. Suppression of synthesis of natural antibodies by mycophenolate mofetil (RS-61443). Transplantation 1993;55:1371-4.
53. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm A, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992;53:428-32.
54. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991;51:27-31.
55. Thomson AW, Starzl TE. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 1993;136:71-98.
56. Kokado Y, Ishiahi M, Jiang H, et al. Low dose cyclosporine, mizoribine, and prednisone in renal transplantation: a new triple drug therapy. Clin Transplant 1990;4:191-7.
57. Umeda Y, Moriguchi M, Kuroda H, et al. Synthesis and antitumor activity of spergualin analogues. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. J Antibiot (Tokyo) 1985;38:886-98.
58. Takeuchi T, Iinuma H, Kunimoto S, et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot (Tokyo) 1981;34:1619-21.
59. Nadler SG, Tepper MA, Schacter B, Mazzucco CE. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992;258:484-6.
60. Lydyard PM, van Eden W. Heat-shock proteins: immunity and immunopathology. Immunol Today 1990;11:228-9.
61. Hightower LE. Heat shock, stress proteins, chaperones, and preteotoxicity. Cell 1991;66:191-7.
62. Ellis RJ. Molecular chaperones. Cell Biol 1990;1:1-9.
63. Tufverson G, Gannedahl G. Deoxyspergualin - a different and intriguing immunosuppressant. Transplant Proc 1994;26(5):3029-39.
64. Suzuki S. Deoxyspergualin: mode of action and effects on graft rejection. In: Thomson AW, Starzl TE, eds. Immunosuppressive drugs: developments in anti-rejection therapy. Boston: Little, Brown, 1994:187-202.
65. Amemiya H, Dohi K, Otsubo O, et al. Markedly enhanced therapeutic effect of deoxyspergualin on acute rejection when combined with methyprednisolone in kidney recipients. Transplant Proc 1991;23:1087-9.
66. Xiao F, Chong AS-F, Bartlett RR, Williams JW. Leflunomide: a promising immunosuppressant in transplantation. In: Thomson AW, Starzl TE, eds. Immunosuppressive drugs: developments in anti-rejection therapy. Boston: Little, Brown, 1994:203-12.
67. Kupiec-Weglinski JW, Badger AM. SK&F 105685: a novel azaspirane with therapeutic effects in transplantation models. In: Sollinger H, Przepiorka D, eds. Recent developments in transplantation medicine. Volume 1. New immunosuppressive drugs. Glenview, IL: Physicians & Scientists Publishing, 1994:179-90.
68. Schmidbauer G, Hancock WW, Badger AM, Kupiec-Weglinski JW. Induction of nonspecific X-irradiation-resistant suppressor cell activity in vivo and prolongation of vascularized allograft survival by SK&F 105685, a novel immunomodulatory azaspirane. Transplantation 1993;55: 1236-43.
69. Schreier MH, Quesniaux VFJ, Baumann G, et al. Molecular basis of immunosuppression. Transplant Sci 1993;3:185-9.
70. Lu CY, Sicher SC, Vazquez MA. Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights in established therapies. J Am Soc Nephrol 1993;4:1239-56.
71. Amemiya H, Suzuki S, Ota K, et al. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990;49: 337-43.
72. Chou TC, Stepkowski SM, Kahan BD. Computerized quantitation of immunosuppressive synergy for clinical protocol design. Transplant Proc 1994;26(5):3043-5.
73. Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley & Sons, 1986:432.
74. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991;51:486-90.
75. Kahan BD, Gibbons S, Tejpal N, Stepkowski SM, Chou TC. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991;51:232-9.
76. Stepkowski SM, Tu Y, Chou TC, Kahan BD. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice. Transplant Proc 1994;26(5):3025-7.
77. Kahan BD, Chou T, Tejpal N, Wang M, Chee C, Stepkowski S. Synergistic effects of cyclosporine analogs - A,D,G, IMM-125 - with rapamycin and/or brequinar. Transplant Proc 1994;26(5):3021-4.
78. Fujino Y, Kawamura T, Hullett DA, Sollinger HW. Evaluation of cyclosporine, mycophenolate mofetil, and brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation. Transplantation 1994;57(1): 41-6.
79. Kahan BD, Tejpal N, Gibbons-Stubbers S, et al. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination. Transplantation 1993;55:894-900.
80. Ferrasesso M, Knight R, Tu Y, Stepkowski SM, Kahan BD. Triple combination of cyclosporine, brequinar, and rapamycin prolongs kidney allograft survival in the mongrel dog. Transplant Proc 1994;26(5):3028.
81. Gregory CR, Huie PH, Billingham ME, Morris RE. Rapamycin inhibits arterial intimai thickening caused by both alloimmune and mechanical injury. Transplantation 1993;55:1409-18.
82. Propper DJ, Woo J, Macleod AM, Catto GRD, Thomson AW. The effects of rapamycin on humoral immunity in vivo. Transplantation 1992;54:1058-63.
83. Ferraresso M, Tian L, Ghobrial R, Stepkowski SM, Kahan BD. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. J Immunol 1994;153:3307-18.
84. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342:1514-16.
85. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
86. Cockfield SM, Preikaitis JK, Jewell LD, Parfrey NA. Posttransplant lymphoproliferative disorder in renal allograft recipients. Transplantation 1993;56:88-96.
87. Hanto DW, Gajl-Peczalska KJ, Frizzera G, Simmons RL, Najarian JS. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg 1983;198:356-69.
88. Ring CJA. The B cell-immortalizing functions of Epstein-Barr virus. J Gen Virol 1994;75:1-13.
89. Alfieri C, Allison AC, Kieffe E. Effect of mycophenolic acid on Epstein-Barr virus infection of human B-lymphocytes. Antimicrob Agents Chemother 1994;38(1):126-9.
90. Clark EA, Ledbetter JA. How B and T cells talk to each other. Nature 1994;367:425-8.
91. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34.
92. Sugita K, Nojima Y, Tachibana K, et al. Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest 1994;94:481-8.
93. Hemler ME. VLA proteins in the integrin family: structures, functions and their role on leukocytes. Annu Rev Immunol 1990;8:365-400.
94. Hynes RO. Integrins: a family of cell surface receptors. Cell 1987;48:549-54.
95. Heffron TG, Thistlewaite JR. New monoclonal antibodies. Transplant Sci 1991;1:64-70.
96. Masroor S, Schroeder TJ, Michler RE, Alexander JW, First MR. Monoclonal antibodies in organ transplantation: an overview. Transplant Immunol 1994;2:176-89.
97. Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994;46:540-53.
98. Cosimi AB. The clinical usefulness of antilymphocyte antibodies. Transplant Proc 1983;15:583-7.
99. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS. Biological and immunological characterization of ATG and ALG. Blood 1986;68:712-19.
100. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86:10029-33.
101. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669-73.
102. Norman DJ. Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol 1992;12:315-24.
103. Cardella CJ, Harding ME, deVeber GA, et al. A controlled trial comparing sequential anti-lymphocytes sera and cyclosporine therapy to conventional therapy in renal transplant recipients. Transplant Proc 1987;19:1996-7.
104. Kreis H. Antilymphocyte globulins in kidney transplantation. Kidney Int Suppl 1992;38:S188-92.
105. Cardella CJ, Rochon J, Shoker A, et al. The sensitized patient: a single center study. In: Terasaki P, ed. Clinical transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1988:171-9.
106. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994;57(5):685-94.
107. Thomas FT, Griesedieck C, Thomas J, et al. Differential effects of horse ATG and rabbit ATG on T cell and T cell subset levels measured by monoclonal antibodies. Transplant Proc 1984;16:1561-3.
108. Macdonald PS, Mundy J, Keogh AM, Chang VP, Spratt PM. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation-increased morbidity with OKT3. Transplantation 1993;55:110-16.
109. Cole EH, Cattran DC, Farewell VT, et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994;57:60-7.
110. Deierhoi MH, Barber WH, Curtis JJ, et al. Treatment of acute rejection by monoclonals. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection. Am J Kidney Dis 1988;11:86-9.
111. Kreis H, Legendre C, Chatenoud L. OKT3 in organ transplantation. Transplant Rev 1991;5:181.
112. Najarian JS, Simmons RL, eds. OKT3: worldwide experience in the management of organ transplant recipients. Clin Transplant 1993;7(part 2).
113. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994;57(11):1537-43.
114. 2b monoclonal antibody (BMA 031) directed toward the human α/β-T cell receptor. Transplantation 1994;57:1581-8.
115. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992;53:80-6.
116. Morel P, Vincent C, Cordier G, Panaye G, Carosella E, Revillard JP. Anti-CD4 monoclonal antibody administration in renal transplanted patients. Clin Immunol Immunopathol 1990;56:311-22.
117. Sablinski P, Hancock WW, Tilney NL, Kupiec-Weglinski JW. CD4 monoclonal antibodies in organ transplantation - a review of progress. Transplantation 1991;52:579-89.
118. Waldmann TA, Goldman CL. The multichain interleukin 2 receptor: a target for immunotherapy of patients receiving allografts. Am J Kidney Dis 1989;14(suppl 2):45-53.
119. Sugamura K, Asao H, Kondo M, et al. The common γ-chain for multiple cytokine receptors. Adv Immunol 1995;59: 225-77.
120. Waldmann TA. The interleukin-2 receptor. J Biol Chem 1991;266:2681-4.
121. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Trends Pharmacol Sci 1993;14:159-64.
122. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplant Proc 1991;23: 1066-7.
123. Kirkman RL, Shapiro ME, Carpenter CB, et al. Early experience with anti-Tac in clinical renal transplantation. Transplant Proc 1989;21:1766-8.
124. Cantarovich D, Le Mauff B, Hourmant M, et al. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. Transplantation 1994;57(2):198-203.
125. Soulillou J-P, Cantarovich D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990;322:1175-82.
126. Kriaa F, Hiesse C, Alard P, et al. Prophylactic use of the antiIL2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study. Transplant Proc 1993;25:817-19.
127. LeMauff B, Hourmant M, Rougier JP, et al. Effect of antiLFA1 (CD11a) monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991;52: 291-6.
128. Maraninchi D, Mawas C, Stoppa AM, et al. Anti-LFA1 monoclonal antibody and bone marrow graft rejection in adults. Lancet 1988;2(8610):579-80.
129. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992;255:1125-7.
130. Hale G, Xia MQ, Tighe HP, et al. The Campath-1 antigen (CDw52). Tissue Antigen 1990;35:118-27.
131. Friend PJ, Waldmann H, Hale G, et al. Reversal of allograft rejection using the monoclonal antibody, Campath-1G. Transplant Proc 1991;23:2253-4.
132. Friend PJ, Hale G, Waldmann H, et al. Campath-1M: prophylactic use after kidney transplantation - a randomized controlled clinical trial. Transplantation 1989;48:248-53.
133. Hale G, Clark MR, Marcus R, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody, Campath-1H. Lancet 1988;2(8625):1394-9.
134. Bretscher P, Cohn M. A theory of self-nonself discrimination: paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 1970;169:1042-9.
135. Lenschow DJ, Bluestone JA. T cell co-stimulation and in vivo tolerance. Transplantation 1993;5:747-52.
136. Lasalle JM, Hafler DA. T cell anergy. FASEB J 1994;8:601-8.
137. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-73.
138. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994;57(12):1701-6.
139. Tykocinski ML, Kaplan DR. Prospects for anti-rejection therapies based upon CD8-dependent immunoregulation. Kidney Int 1993;43(39):S120-3.
140. Chester KA, Hawkins RE. Clinical issues in antibody design. Trends Biotechnol 1995;13(8):294-300.
141. Goss JA, Nakafusa Y, Flye MW. Intrathymic injection of donor alloantigens induces donor-specific vascularized allograft tolerance without immunosuppression. Ann Surg 1992;216:409-16.
142. Chaudhy VK, Queen C, Junghans RP, et al. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989;339:394-7.
143. Isaacs JD, Watts RA, Hazleman BL, et al. Humanized monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992;340:748-52.
144. Mathieson PW, Cobbold SP, Hale G. Monoclonal antibody therapy in systemic vasculitis. N Engl J Med 1990;323: 250-4.
145. Richardson JH, Marasco WA. Intracellular antibodies: development and therapeutic potential. Trends Biotechnol 1995;13:306-10.
146. Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991;252:1657-62.
147. Winter G, Milstein C. Man-made antibodies. Nature 1991;349:293-9.
148. Trospha A, Kizer JS, Chaiken IM. Making sense from antisense: a review of experimental data and developing ideas on sense-antisense peptide recognition. J Mol Recognit 1992;5:43-54.
149. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 1994;15:42-6.
150. Moffat ASV. Making sense of antisense. Science 1991; 253:510-11.
151. Qin L, Chavin KD, Ding Y, et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Transplantation 1995;59(6):809-16.